Suchergebnisse - "Herzer, Kerstin"

PubPharm (15)

1

Safety and efficacy of tenofovir alafenamide in liver transplant recipients : A single center experience

enthalten in: Transplant infectious disease : an official journal of the Transplantation Society | 2021

von Rashidi-Alavijeh, J. | Straub, K. | Achterfeld, A. | +3

2

Comparison of Three Cellular Assays to Predict the Course of CMV Infection in Liver Transplant Recipients

enthalten in: Vaccines | 2021

von Gliga, S. | Fiedler, M. | Dornieden, T. | +5

3

Real-World Administration of Once-Daily MeltDose® Prolonged-Release Tacrolimus (LCPT) Allows for Dose Reduction of Tacrolimus and Stabilizes Graft Function Following Liver Transplantation

enthalten in: Journal of clinical medicine | 2020

von Willuweit, K. | Frey, A. | Hörster, A. | +2

4

Current Challenges in the Post-Transplant Care of Liver Transplant Recipients in Germany

enthalten in: Journal of clinical medicine | 2020

von Herzer, K. | Sterneck, M. | Welker, M. | +9

5

Current challenges in the post-transplant care of liver transplant recipients in Germany

enthalten in: Journal of Clinical Medicine | 5 November 2020

von Herzer, K. | Sterneck, M. | Welker, M. | +9

6

Improving the vaccination status of liver transplant patients : Effectiveness of personally addressing patients and written recommendations to family physicians after 3 years

enthalten in: Transplant infectious disease : an official journal of the Transplantation Society | 2019

von Dehnen, D. | Herwig, A. | Herzer, K. | +1

7

The influence of immunosuppressants on direct-acting antiviral therapy is dependent on the hepatitis C virus genotype

enthalten in: Transplant infectious disease : an official journal of the Transplantation Society | 2018

von Frey, A. | Piras-Straub, K. | Walker, A. | +3

8

Immunosuppression with mTOR inhibitors prevents the development of donor-specific antibodies after liver transplant

enthalten in: Clinical transplantation | 2017

von Willuweit, K. | Heinold, A. | Rashidi-Alavijeh, J. | +5

9

Efficacy, safety, and pharmacokinetics of simeprevir, daclatasvir, and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation : The Phase II SATURN study

enthalten in: Transplant infectious disease : an official journal of the Transplantation Society | 2017

von Forns, X. | Berenguer, M. | Herzer, K. | +16

10

A -1573T>C SNP within the human TRAIL promoter determines TRAIL expression and HCC tumor progression

enthalten in: Cancer medicine | 2016

von Piras-Straub, K. | Khairzada, K. | Kocabayoglu, P. | +3